UB561
TargetsTYK2/JAK1
IndicationsAtopic dermatitis; Inflammatory bowel disease; Systemic lupus erythematosus
ClinicalCN - II
TherapeuticsImmunology & Inflammation
ModalitiesSmall Molecule
Exclusive Summary
- • A Potent TYK2/JAK1 JH2 allosteric inhibitor
- • The inhibitory activity against JAK1 JH2 is significantly superior to that of Deucravacitinib.
- • The efflux ratio is low, enabling it to maintain effective concentrations for ulcerative colitis treatment at low doses.
- • The exposure and half-life is significantly improved.
- • The clinical efficacy is significantly superior to that of Deucravacitinib in PSO, IBD data of Ph1b is under evaluation.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →